-
Outlook Therapeutics NasdaqCM:OTLK Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic bevacizumab product formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration agreements with Cencora. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is headquartered in Iselin, New Jersey.
Location: 111 S. Wood Avenue, Building F, Suite 320, Iselin, NJ, 08830, United States | Website: https://www.outlooktherapeutics.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
82.49M
Cash
7.556M
Avg Qtr Burn
-16.01M
Short % of Float
15.40%
Insider Ownership
38.31%
Institutional Own.
16.81%
Qtr Updated
03/31/25
Drug Pipeline
Powered by
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
| Drug & Indication | Stage & Event | Catalyst Date |
|---|---|---|
ONS-5010 / LYTENAVA™ (bevacizumab-vikg) Details Eye disease , Wet age-related macular degeneration | PDUFA Approval decision |